Veracyte, Inc. (VCYT) Analysts See $-0.23 EPS

April 17, 2018 - By Rodney Autry

Veracyte, Inc. (NASDAQ:VCYT) LogoInvestors sentiment decreased to 1.23 in Q4 2017. Its down 0.53, from 1.76 in 2017Q3. It dropped, as 15 investors sold Veracyte, Inc. shares while 16 reduced holdings. 12 funds opened positions while 26 raised stakes. 21.45 million shares or 4.52% less from 22.46 million shares in 2017Q3 were reported.
Parallax Volatility Advisers L P holds 3,570 shares or 0% of its portfolio. Bnp Paribas Arbitrage accumulated 0% or 4,633 shares. Invesco holds 0% or 11,636 shares in its portfolio. Moreover, Goldman Sachs Gru has 0% invested in Veracyte, Inc. (NASDAQ:VCYT). One Trading L P owns 50,129 shares. Moreover, California State Teachers Retirement Systems has 0% invested in Veracyte, Inc. (NASDAQ:VCYT) for 37,021 shares. Deutsche Savings Bank Ag reported 115,597 shares. Moreover, Panagora Asset Mgmt has 0% invested in Veracyte, Inc. (NASDAQ:VCYT). Geode Management Limited Liability Com reported 153,487 shares. Boston Advisors accumulated 60,800 shares. Sei invested in 0% or 129 shares. Voya Invest Limited Liability Co holds 0% or 11,713 shares in its portfolio. 9,127 were accumulated by Royal Comml Bank Of Canada. Legal And General Group Plc has 4,853 shares for 0% of their portfolio. Ameritas Prtnrs Inc owns 0% invested in Veracyte, Inc. (NASDAQ:VCYT) for 1,394 shares.

Analysts expect Veracyte, Inc. (NASDAQ:VCYT) to report $-0.23 EPS on May, 2.They anticipate $0.01 EPS change or 4.17 % from last quarter’s $-0.24 EPS. After having $-0.24 EPS previously, Veracyte, Inc.’s analysts see -4.17 % EPS growth. The stock increased 0.70% or $0.04 during the last trading session, reaching $5.73. About 137,112 shares traded or 26.66% up from the average. Veracyte, Inc. (NASDAQ:VCYT) has declined 39.30% since April 18, 2017 and is downtrending. It has underperformed by 50.85% the S&P500.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

Among 3 analysts covering Veracyte (NASDAQ:VCYT), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Veracyte had 3 analyst reports since November 7, 2017 according to SRatingsIntel. Leerink Swann maintained it with “Outperform” rating and $9 target in Tuesday, November 7 report. The company was downgraded on Tuesday, November 7 by Piper Jaffray. The stock has “Neutral” rating by Janney Capital on Tuesday, November 7.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $196.49 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.